Key insights
- The FDA accepted Gilead's new drug application for a once-daily HIV treatment, setting an action date in August 2026. Positive Phase 3 trial data supports the application. While this strengthens Gilead's HIV portfolio, the long approval timeline and limited immediate impact on earnings result in a slightly positive influence on the broader US equity market.
FOSTER CITY, Calif. - Gilead Sciences (NASDAQ:GILD) announced Monday that the U.S. Food and Drug Administration accepted its New Drug Application for bictegravir 75 mg/lenacapavir 50 mg, an investigational once-daily single-tablet regimen for treating HIV in virologically suppressed adults, according to a press release statement. The $160 billion biotech giant, trading at a P/E ratio of 19, continues to strengthen its HIV portfolio with this latest regulatory milestone.
The FDA granted priority review and set an action date of August 27, 2026, under the Prescription Drug User Fee Act. The combination pairs bictegravir, an integrase strand transfer inhibitor, with lenacapavir, a capsid inhibitor.
The application is supported by Phase 3 data from the ARTISTRY-1 and ARTISTRY-2 trials. Both studies evaluated the combination in adults with HIV who had virological suppression, including patients switching from multi-tablet regimens or from Biktarvy. The trials showed the combination maintained virological suppression at Week 48 and was generally well tolerated, with no significant or new safety concerns identified.According to InvestingPro analysis, Gilead currently trades below its Fair Value and maintains a "GREAT" financial health score. For investors seeking deeper insights, comprehensive Pro Research Reports are available for GILD and 1,400+ other US equities.
ARTISTRY-1 enrolled the oldest study population in a Phase 3 HIV treatment registrational trial to date. Week 48 data presented at CROI 2026 showed the treatment switch was associated with improvements in certain fasting lipid parameters and patient-reported treatment satisfaction. ARTISTRY-2 showed switching to the combination had no significant impact on weight.
Bictegravir plus lenacapavir in combination are investigational and not approved anywhere globally. Lenacapavir is currently approved in multiple countries for treating multi-drug-resistant HIV in adults when used with other antiretrovirals, and as pre-exposure prophylaxis to reduce the risk of sexually acquired HIV in adults and adolescents.
Biktarvy, which contains bictegravir with emtricitabine and tenofovir alafenamide, is currently available as a complete HIV treatment regimen.
In other recent news, Gilead Sciences Inc. has extended the expiration of its tender offer to acquire Arcellx until April 27, 2026, after securing all necessary regulatory approvals. The Australian Competition and Consumer Commission has approved the transaction, with a waiting period that concludes on the same date. In another development, Gilead announced a significant expansion in the access to its HIV prevention drug, lenacapavir, aiming to reach an additional 1 million people through partnerships with the U.S. State Department, PEPFAR, and The Global Fund. This effort will bring the total reach to 3 million individuals in high-incidence, resource-limited countries by 2028. Additionally, Gilead has expanded its collaboration with Tempus AI to enhance its oncology research and development, gaining access to Tempus’ AI-driven Lens platform. This collaboration aims to leverage broader datasets and analytical services to advance Gilead’s oncology pipeline. Meanwhile, RBC Capital has maintained a Sector Perform rating on Gilead Sciences, with a price target of $123.00, focusing on the performance of Yeztugo in the PrEP market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.